TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Short Interest Up 45.5% in December

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) saw a significant increase in short interest in the month of December. As of December 31st, there was short interest totalling 83,800 shares, an increase of 45.5% from the December 15th total of 57,600 shares. Based on an average trading volume of 37,300 shares, the short-interest ratio is presently 2.2 days. Approximately 2.4% of the shares of the company are short sold.

Wall Street Analysts Forecast Growth

TLSI has been the topic of a number of analyst reports. Roth Capital raised shares of TriSalus Life Sciences to a “strong-buy” rating in a report on Monday, November 11th. Northland Securities started coverage on shares of TriSalus Life Sciences in a research note on Friday, October 25th. They issued an “outperform” rating and a $12.50 price target on the stock. Northland Capmk upgraded TriSalus Life Sciences to a “strong-buy” rating in a research report on Friday, October 25th. Cantor Fitzgerald initiated coverage on TriSalus Life Sciences in a research report on Tuesday, December 17th. They issued an “overweight” rating and a $10.00 target price on the stock. Finally, Canaccord Genuity Group reduced their price target on TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating for the company in a research report on Friday, November 15th. Seven analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $11.79.

Insider Buying and Selling at TriSalus Life Sciences

In related news, major shareholder Equity Ab Frankenius bought 62,972 shares of the company’s stock in a transaction on Tuesday, December 17th. The shares were purchased at an average cost of $3.97 per share, with a total value of $249,998.84. Following the completion of the transaction, the insider now directly owns 6,230,748 shares of the company’s stock, valued at approximately $24,736,069.56. This represents a 1.02 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders purchased a total of 70,012 shares of company stock worth $281,235 over the last ninety days. Company insiders own 32.80% of the company’s stock.

Institutional Trading of TriSalus Life Sciences

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Highbridge Capital Management LLC bought a new position in TriSalus Life Sciences during the second quarter valued at about $1,184,000. Duquesne Family Office LLC lifted its holdings in TriSalus Life Sciences by 35.1% in the 2nd quarter. Duquesne Family Office LLC now owns 426,921 shares of the company’s stock valued at $2,357,000 after acquiring an additional 110,966 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of TriSalus Life Sciences by 45.4% during the 3rd quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock valued at $924,000 after purchasing an additional 62,542 shares in the last quarter. MSD Partners L.P. acquired a new position in shares of TriSalus Life Sciences in the 3rd quarter worth approximately $184,000. Finally, Vestcor Inc acquired a new stake in TriSalus Life Sciences during the third quarter valued at approximately $108,000. Institutional investors own 2.58% of the company’s stock.

TriSalus Life Sciences Price Performance

Shares of NASDAQ:TLSI opened at $4.83 on Friday. TriSalus Life Sciences has a 12 month low of $3.50 and a 12 month high of $10.42. The stock’s 50 day moving average price is $4.41 and its 200 day moving average price is $4.78.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.